Chromocell Therapeutics Corporation (CHRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chromocell Therapeutics Corporation (CHRO) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-447.14K) by net assets ($-6.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Chromocell Therapeutics Corporation (CHRO) share price today for real-time trading data and today's change.
Chromocell Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Chromocell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Chromocell Therapeutics Corporation market capitalisation for the company's overall valuation and market capitalisation.
Chromocell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chromocell Therapeutics Corporation ranked by their cash flow conversion efficiency. Also see Chromocell Therapeutics Corporation balance sheet assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
reAlpha Tech Corp. Common Stock
NASDAQ:AIRE
|
-0.335x |
|
PT Dafam Property Indonesia Tbk
JK:DFAM
|
1.537x |
|
Ancom Logistics Bhd
KLSE:0048
|
0.361x |
|
Energoinstal S.A.
WAR:ENI
|
0.031x |
|
ITM Power
LSE:ITM
|
-0.009x |
|
ZHONGLIANG HLDG HD-01
F:3ZH
|
N/A |
|
OPTHEA LTD
F:UKJ
|
N/A |
|
Gambling.com Group Ltd
NASDAQ:GAMB
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Chromocell Therapeutics Corporation (2020–2024)
The table below shows the annual cash flow conversion efficiency of Chromocell Therapeutics Corporation from 2020 to 2024. Review Chromocell Therapeutics Corporation leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | 0.00% |
| 2023-09-30 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | 0.00% |
| 2022-09-30 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | 0.00% |
| 2021-09-30 | $-3.68 Million | $-1.59 Million | 0.433x | -57.29% |
| 2020-12-31 | $-3.58 Million | $-3.63 Million | 1.013x | 0.00% |
| 2020-09-30 | $-3.58 Million | $-3.63 Million | 1.013x | -- |
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and id… Read more